HORIZON EUROPE
Europeo
Scope:Innovation Actions of one of the following two categories to:
1) Support solutions that are close-to-market (TRL 7) in one of the COVID-19 areas mentioned below and that have already received, or are about to receive, the CE marking to proceed to large scale testing, piloting and deployment operations in critical healthcare areas (or wherever else is relevant) (type 1);
2) Support market innovation (from lab-to-fab) for further developing and maturing innovative solutions that have already been validated in lab environments (TRL 6-7 or higher) with the aim to help accelerate developments and achieve conformity assessment (CE marking) (type 2).
This topic addresses consortia consisting of innovative technology providers, including SMEs, and/or organisations that can offer the range of activities required to address the objectives of the topic; the latter could for example be based on Digital Innovation Hubs, digital health accelerators and knowledge hubs, Centres offering Pilot Lines or similar technology, business and/or knowledge transfer organisations. The innovative technology providers can be either members of the applicant consort...
ver más
Scope:Innovation Actions of one of the following two categories to:
1) Support solutions that are close-to-market (TRL 7) in one of the COVID-19 areas mentioned below and that have already received, or are about to receive, the CE marking to proceed to large scale testing, piloting and deployment operations in critical healthcare areas (or wherever else is relevant) (type 1);
2) Support market innovation (from lab-to-fab) for further developing and maturing innovative solutions that have already been validated in lab environments (TRL 6-7 or higher) with the aim to help accelerate developments and achieve conformity assessment (CE marking) (type 2).
This topic addresses consortia consisting of innovative technology providers, including SMEs, and/or organisations that can offer the range of activities required to address the objectives of the topic; the latter could for example be based on Digital Innovation Hubs, digital health accelerators and knowledge hubs, Centres offering Pilot Lines or similar technology, business and/or knowledge transfer organisations. The innovative technology providers can be either members of the applicant consortia or selected through open calls organised by the consortium using financial support to third parties. The support offered could include access to product development, accelerator, incubator and technical services and capabilities such as testing and experimentation facilities together with expertise, prototyping, design, engineering or pilot manufacturing services as necessary, as well as providing support for medical certification and clinical validation. Any use of third party grants must result in minimal administrative burden for participants, and allow the fastest possible launch of the projects.
The proposed actions could encompass a combination of tools and technologies, such as: microelectronics, micro/nano/cyber-physical systems; bio-functionalized chips and biosensor arrays; bio-photonics; graphene or related materials (GRM); data, AI and robotics; pathogen detection technologies; e-health, telemedicine and digital solutions.
The proposals should address one or more of the following areas:
fast, cost-effective and easily deployable sampling, screening, diagnostic and prognostic systems, including new methods for screening of lungs, using for example AI or advanced photonics solutions, to detect the presence of the pathogen related parameters especially in an early stage of infection;environmental surveillance (sewage, air, etc.) systems and data analytics as a sentinel for viral (re)emergence and spread in communities, based for example on optical biosensors or genetic detection;low cost sensors, smart wearable devices and robotics/AI for telemedicine, telepresence and continuous remote monitoring of patient parameters;protection of healthcare practitioners and the general public improving for example the wetting and filtering properties of fabrics used for face masks; sensors, sterilisation, including robotics and AI solutions, for disinfection and social distancing in environments such as healthcare, public spaces and buildings;innovative data-driven services and tools combining data assets from various relevant privately held and/or publicly available sources. These could include AI-based solutions exploiting such data and possibly additional sensor-based signals, for diagnostics, prevention, treatment, or rehabilitation. Where appropriate, privacy, data protection and anonymity in the use of mobile warning and prevention applications, as referred to in the Commission Recommendation C(2020) 2296 of 8 April 2020 on a common Union toolbox for the use of technology and data to combat and exit from the COVID-19 crisis, should be ensured. Expected EU contribution per proposal
The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 5 million would allow these specific challenges to be addressed appropriately. For proposals with financial support to third parties, up to EUR 10 million may be requested. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
The proposers must specify which type of category 1) or 2) above they are addressing; at least one proposal will be selected in each category.
For grants awarded under this topic, beneficiaries may provide financial support to third parties as described in part K of the General Annexes of the Work Programme, typically in the order of EUR 20.000 to 100.000 per third party. This is to ensure that the innovators selected though open calls have appropriate resources for addressing the scope and reaching the specific objectives of this topic. The support to third parties may only be provided in the form of grants. The respective options of Article 15.1 and Article 15.3 of the Model Grant Agreement will be applied.
The maximum duration is 2 years.
Applicant consortia planning to launch competitive calls should be ready to do so within a month after the start of the project and proceed to fast-track proposal selection and launch of the selected projects. To this end, they should explicitly provide evidence in the proposal as to how they will reach a very large number of potentially interested organisations and demonstrate convincingly that they can handle actions of this kind and scale (e.g. through a proven track record).
Expected Impact:To contribute to the public health preparedness and response in the context of the ongoing epidemic of COVID-19 and to ensure the availability of critical technologies and tools.To contribute to the acceptability, adoption, appropriateness, feasibility, fidelity, implementation cost, coverage, and sustainability of diagnosis and clinical management of patients and survivors of COVID-19. To contribute to proposing recommendations for changes that would allow a fast recovery and a better preparedness, including in the health care systems, for future health emergencies. To accelerate the deployment and market uptake of mature health technologies for the prevention and optimised treatment of the COVID-19 disease, by delivering results within 3-24 months to end-users at scale.
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits: under this topic, the limit for a full proposal is 45 pages.
Proposal layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion will be 3 (Excellence), 3 (Impact) and 3 (Implementation). The cumulative threshold will be 10.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (Public Health Emergency): 2 months from the deadline for submission.
Signature of grant agreements: 4 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Innovation Action:
Specific provisions and funding rates
Specific proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
These documents are for reference only; for submission of proposals, the documents provided in the submission system should be used.
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL)... 1. Eligible countries: described in Annex A of the Work Programme.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Proposal page limits: under this topic, the limit for a full proposal is 45 pages.
Proposal layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion will be 3 (Excellence), 3 (Impact) and 3 (Implementation). The cumulative threshold will be 10.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (Public Health Emergency): 2 months from the deadline for submission.
Signature of grant agreements: 4 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Innovation Action:
Specific provisions and funding rates
Specific proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
These documents are for reference only; for submission of proposals, the documents provided in the submission system should be used.
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Annex K of the Work Programme on Actions involving financial support to third parties.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
7. Additional obligations
Data sharing
Beneficiaries in grants awarded under this call for expression of interest must make available their research data, at the latest within 30 days after it has been generated, through open access or, if agreed by the Commission, by giving access rights to those third parties that need the research data to address the public health emergency. Therefore the relevant option of Article 29.3 (option 1c) of the H2020 Model Grant Agreement will apply.
The use of harmonised protocols in collaboration with other actors is recommended for this purpose.
Beneficiaries must make the research data accessible and re-usable through appropriate platforms (such as the data-sharing platform), following guidelines communicated by the Commission.
The relevant option of Article 29.1 of the H2020 Model Grant Agreement will apply.
It is expected that quality-controlled data are shared in accordance with the FAIR principles.
A draft data management plan (DMP) must be submitted preferably with the proposal and at the latest before the signature of the grant agreement. The DMP should address the relevant aspects of making the data FAIR – findable, accessible, interoperable and re-usable, including what data the project will generate, whether and how the data will be made accessible for verification and re-use, and how it will be circulated and preserved. A template for such a plan is given in the guidelines on data management in the H2020 Online Manual.
Costs related to data management and data sharing are eligible for reimbursement if incurred during the project duration under the conditions set out in the grant agreement.
Exploitation obligations
In the context of the public health emergency, additional exploitation obligations apply, to ensure that results or resulting products/services (i.e. products or services developed based on results generated in the action) will be available and accessible, as soon as possible and at fair conditions. This will include an obligation to license on a non-exclusive basis and at fair and reasonable conditions.
The scope of the additional exploitation obligations will be discussed in more detail with successful applicants/participants at due time.
To enhance the exploitation of results, beneficiaries must provide a "results ownership list" (ROL) together with the final report and use the Horizon results platform.
The option of Article 28.1 of the Model Grant Agreement will apply and the necessary provisions will be inserted in Annex 1.
Right to object to transfers of ownership and exclusive licences
The relevant option of Article 30.3 of the H2020 Model Grant Agreement will apply.
8. Additional documents:
Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta